AiNaNo.ru
Заметки о нанотехнологиях и не только
-
Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis Company Expects to Initiate Trial in First Half of 2012 with Data in Third Quarter of 2012
Я буду первым!-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products…
Published on Январь 7, 2012 · Категории: Nanotech, Нанотехнологии;
